Cancer
In February 2021, a licensing agreement was entered into with the UK-based Ubiquigent Limited for the preclinical USP-7 research program. Unfortunately, funding challenges have made it impossible for Ubiquigent to continue operations. Medivir is currently evaluating the path forward for the USP-7 project.